This MedLibrary.org supplementary page on Zostavax is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
Zostavax is a live vaccine developed by Merck & Co. which has been shown to reduce the incidence of herpes zoster (known as Shingles) by 51.3% in a pivotal phase III study of 38,000 adults aged 60 and older who received the vaccine. The vaccine also reduced by 66.5% the number of cases of postherpetic neuralgia and reduced the severity and duration of pain and discomfort associated with shingles, by 61.1%.12 Local reactions at the injections site were generally mild.
Zostovax was approved by the FDA in May, 20063. The FDA recommended it only for adults aged 60 who meet the following requirements4:
- Has not had a life-threatening allergic reaction to gelatin, the antibiotic neomycin, or other component of the herpes zoster vaccine.
- Does not have a weakened immune system due to HIV/AIDS or another disease or medications (such as steroids, radiation and chemotherapy) that affect the immune system.
- Does not have a history of cancer affecting the bone marrow or lymphatic system, such as leukemia or lymphoma.
- Does not have active, untreated tuberculosis.
On October 25th, 2006, the CDC's Advisory Committee on Immunization Practices (ACIP) voted to recommend that Zostavax be given to all adults age 60 and over, including those who have had a previous episode of shingles5.
References
- ^ M.N. Oxman et al., The Shingles Prevention Study Group (2005). "A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults". New England Journal of Medicine 352 (22): 2271–2284. doi:. PMID 15930418.
- ^ Oxman MN, Levin MJ (March 2008). "Vaccination against Herpes Zoster and Postherpetic Neuralgia". J. Infect. Dis. 197 Suppl 2: S228–36. doi:. PMID 18419402, http://www.journals.uchicago.edu/doi/abs/10.1086/522159?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov.
- ^ Mitka M. (2006). "FDA Approves Shingles Vaccine: Herpes Zoster Vaccine Targets Older Adults". JAMA 296(2): 157–158. doi:. PMID 16835412.
- ^ Patient Information about ZOSTAVAX
- ^ Advisory Committee on Immunization Practices, CDC (2006). "CDC’s Advisory Committee Recommends “Shingles” Vaccination".
|
|||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 17 September 2008, at 10:50.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Zostavax".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.